advertisement
Abstract #6161 Published in IGR 2-2
Role of aspirin in reducing the frequency of second eye involvement in patients with non-arteritic anterior ischaemic optic neuropathy
Salomon O; Huna-Baron R; Steinberg DM; Kurtz S; Seligsohn UEye 1999; 13: 357-359
PURPOSE: To retrospectively evaluate in patients with non-arteritic ischemic optic neuropathy (NAION) whether aspirin reduces the frequency of second eye involvement. METHODS: In 52 patients who presented with NAION between 1984 and 1997 adequate information was available regarding use of aspirin, presence of risk factors and second eye involvement. RESULTS: Second eye involvement was noted in eight of 16 patients (50%) who did not receive aspirin, in three of eight patients (38%) who received 100 mg/day aspirin and in only five of 28 patients (18%) who received aspirin 325 mg/day. Moreover, mean time to second eye involvement was 63 months in patients who did not receive aspirin versus 156 months in patients who received aspirin 325 mg/day. CONCLUSION: These results strongly suggest that aspirin at 325 mg/day may be effective in reducing the frequency of second eye involvement with NAION.
Dr. O. Salomon, Department of Hematology, Sheba Medical Center, Tel Hashomer, Israel
Classification:
10 Differential diagnosis e.g. anterior and posterior ischemic optic neuropathy
